Guo et al. (32) highlighted the involvement of NLRP3 inflammasome in RA pathogenesis and suggested that targeting NLRP3 inflammasome with MCC950 could be a novel therapeutic strategy for RA. The gene discussed is NLRP3; the disease is rheumatoid arthritis.